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S-adenosyl-L-homocysteine hydrolaseS-adenosyl-L-methionine (AdoMet)-dependent methylation is central to the regulation of many biological
processes: more than 50 AdoMet-dependent methyltransferases methylate a broad spectrum of cellular com-
pounds including nucleic acids, proteins and lipids. Common to all AdoMet-dependent methyltransferase re-
actions is the release of the strong product inhibitor S-adenosyl-L-homocysteine (AdoHcy), as a by-product
of the reaction. S-adenosyl-L-homocysteine hydrolase is the only eukaryotic enzyme capable of reversible
AdoHcy hydrolysis to adenosine and homocysteine and, thus, relief from AdoHcy inhibition. Impaired
S-adenosyl-L-homocysteine hydrolase activity in humans results in AdoHcy accumulation and severe patho-
logical consequences. Hyperhomocysteinemia, which is characterized by elevated levels of homocysteine in
blood, also exhibits a similar phenotype of AdoHcy accumulation due to the reversal of the direction of the
S-adenosyl-L-homocysteine hydrolase reaction. Inhibition of S-adenosyl-L-homocysteine hydrolase is also
linked to antiviral effects. In this review the advantages of yeast as an experimental system to understand
pathologies associated with AdoHcy accumulation will be discussed.
© 2012 Elsevier B.V. Open access under CC BY-NC-ND license.1. AdoMet — a principal methyl group donor and more
Beyond its role in protein synthesis and structure, methionine,
after its activation to AdoMet by methionine adenosyltransferase,
plays a crucial role inmany aspects of cellularmetabolism. AdoMet is syn-
thesized in virtually all living organisms [1]. It is the second most widely
used enzyme substrate after ATP [2] and, thus, one of the most versatile
biomolecules. Being a high-energy sulfonium compound AdoMet can
serve as a source of all three ligands linked to the sulfur atom. AdoMet
is themethyl group donor used by all organisms inmostmethyl transfer
reactions [3]. Itwas also shown to be used in a number of other reactions,
serving as a source of propylamine for the synthesis of spermidine and
spermine, amino groups for the synthesis of biotin, or ribosyl groups
in the synthesis of queuosine, a hypermodiﬁed tRNA, as well as 5′
deoxyadenosyl radicals required for a number of radical reactions [3,4].
The fact that under normal conditions more than 90% of total
AdoMet inmammalian cells is used formethylation reactions catalyzed
by AdoMet-dependent methyltransferases in which AdoMet donates
its methyl group to a large variety of acceptors including nucleic
acids, proteins and lipids underscores the importance of methylation
in downstream reactions of AdoMet [3,5]. AdoHcy, which is released
as a by-product of AdoMet-dependent methyl transfer reactions, is a: +43 316 380 9854.
livets).
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and is hydrolyzed by S-adenosyl-L-homocysteine hydrolase to homo-
cysteine and adenosine (Fig. 1a). Inmammals, homocysteine produced
by this reaction can be remethylated to methionine by methionine
synthase or betaine–homocysteine methyltransferase and, thus, retained
in the methylation cycle. Alternatively, it can be withdrawn from the
methylation cycle by its conversion to cysteine, the precursor of glutathi-
one, via the two-step transsulfuration pathway. Cystathionine β-synthase
is the ﬁrst and rate-limiting enzyme of the latter. Both cystathionine
β-synthase and the enzyme catalyzing the second step of the
transsulfuration pathway, cystathionine γ-lyase, are vitamin B6 re-
quiring enzymes.
AdoMet is synthesized by methionine adenosyltransferase from
ATP and methionine. In mammals, methionine can be either ingested
in the diet or formed by methylation of homocysteine using either
a methyl group of betaine or that of 5-methyltetrahydrofolate. The
latter is formed by methylenetetrahydrofolate reductase from 5,10-
methylenetetrahydrofolate in a cobalamin-dependent reaction [5].
Deﬁciency of methionine synthase that catalyzes remethylation of
homocysteine to methionine using 5-methyltetrahydrofolate links
homocysteine and folate metabolism leading to accumulation of
methyltetrahydrofolate at the expense of the methylenetetrahydrofolate
and tetrahydrofolate pools required for thymidylate and purine bio-
synthesis [6].
The enzymes required for AdoMet synthesis, AdoHcy catabolism,
homocysteine remethylation and transsulfuration are conservedbetween
yeast and mammals except for betaine–homocysteine methyltransferase
Fig. 1. AdoMet-dependent methylation: the role of AdoHcy and S-adenosyl-L-homocysteine hydrolase a) in yeast and b) in mammals. Reverse transsulfuration pathway in yeast
converts cysteine into homocysteine via cystathionine γ-synthase, Str2, and cystathionine β-lyase, Str3. AdoMet, S-adenosyl-L-methionine; AdoHcy, S-adenosyl-L-homocysteine;
Hcy, homocysteine; Met, methionine; Sah1, S-adenosyl-L-homocysteine hydrolase in yeast; AHCY, S-adenosyl-L-homocysteine hydrolase in mammals; CTT, cystathionine; Sam1,
AdoMet synthetase 1; Sam2, AdoMet synthetase 2; Sam4, AdoMet-homocysteine methyltransferase; Mht1, S-methylmethionine–homocysteine methyltransferase; Met6,
methionine synthase; Met25, O-acetylhomoserine sulfhydrylase; Str1, cystathionine γ-lyase; Str2, cystathionine γ-synthase; Str3, cystathionine β-lyase; Str4, cystathionine
β-synthase; Gsh1, γ-glutamylcysteine synthetase; MAT, methionine adenosyltransferase; MS, methionine synthase; BHMT, betaine-homocysteine methyltransferase; CBS,
cystathionine β-synthase; CTH, cystathionine γ-lyase; GCS, γ-glutamylcysteine synthetase.
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ference between sulfur metabolism in mammals and in yeast is the
presence of the sulfur assimilation pathway in the latter (Fig. 1b); how-
ever, this pathway can be efﬁciently eliminated in yeast by the intro-
duction of a mutation disrupting the pathway [7]. Deﬁciencies in the
enzymes involved in the methylation cycle or homocysteine catabo-
lism e.g. cystathionine β-synthase, methionine adenosyltransferase,
methylenetetrahydrofolate reductase and S-adenosyl-L-homocysteine
hydrolase show that many of them are linked to a number of patholo-
gies including deregulation of lipid metabolism [7–13], neurological
abnormalities [10,14–16], tumorigenicity [8,9,11], oxidative stress [8]
and myopathy [14].
2. AdoMet-dependent methyltransferases
Computational analysis of the human proteome revealed 208
known and putative human AdoMet-dependent methyltransferases
that make up about 0.9% of genes in the human genome [17]. Note-
worthy, 30% of these proteins have been linked to disease states
e.g. cancer and mental disorders [17]. Analysis of the yeast proteome re-
vealed 81 known and putative AdoMet-dependent methyltransferases,
making up about 1.2% of genes in the yeast genome [18]. The increased
number of AdoMet-dependent methyltransferases in humans as com-
pared to yeast reﬂects partial redundancy as well as novel functions pres-
ent in the human methyltransferasome in comparison with yeast [17].
AdoMet-dependent methyltransferases such as DNA-, glycine-,
guanidinoacetate- and isoaspartyl methyltransferases are found only in
humans. However, sterol-24C-methyltransferase, Erg6p, is found only in
yeast. Nevertheless, the majority of AdoMet-dependent methyl-
transferases are conserved between yeast and humans. In Table 1, yeastandhumanAdoMet-dependentmethyltransferases groupedby their sub-
strate speciﬁcity are compared. The whole list of known and putative
yeast and human AdoMet-dependent methyltransferases can be found
in [18] and [17], respectively.
The largest group of AdoMet-dependent methyltransferases methyl-
ates proteins, predominantly at the ε-amine group of lysine and ω- or
δ-guanidine groups of arginine as well as on the C-terminal leucine and
isoprenylated cysteine residues. Targets of AdoMet-dependent pro-
tein methyltransferases include histones, ribosomal proteins, tran-
scription and translation factors, signal transduction proteins etc.
[19–22]. For instance, the SET domain protein lysinemethyltransferase
family, which makes up 27% of human methyltransferasome and 14%
of yeast methyltransferasome, methylates predominantly histones at
lysine residues [17,23]. Comparison of a number of histone lysine
methyltransferases from various organisms ranging from yeast to
human underlines the similarity of their roles in the maintenance of
normal cellular functions in eukaryotes [24].
Protein arginine methyltransferases methylate in addition to his-
tones [19,20] numerous non-histone proteins [20,22,25] both in
yeast and in mammals, including heterogeneous nuclear riboproteins
(hnRNPs) required for eukaryotic transcription elongation, mRNA pro-
cessing and export [26–28]. Further targets for AdoMet-dependentmeth-
ylation are the protein phosphatase 2A (PP2A), which is methylated
at the highly conserved C-terminal leucine of its catalytic C subunits
[29], and G proteins, in particular Ras proteins, that are methylated at
C-terminal isoprenylcysteine residues [30].
A big group of AdoMet-dependent methyltransferases methylate
nucleic acids. However, while many AdoMet-dependent methyltrans-
ferases are involved in the methylation of mRNA, rRNA and tRNA
both in yeast and inmammals, there are no orthologs tomammalian
Table 1
Comparison of yeast and human AdoMet-dependent methyltransferases grouped by substrate speciﬁcity. The whole list of known and putative yeast and human
AdoMet-dependent methyltransferases can be found in [18] and [17], respectively.
AdoMet-dependent methyltransferases Biological function/process Yeast Mammalian orthologs
DNA
DNA (cytosine-5-)-methyltransferases Gene silencing – DNMT1, DNMT2, DNMT3a, DNMT3b
RNA
mRNA (guanine-N7-)-methyltransferases Methylation of the 5′ cap structure of mRNA Abd1 RNMT
mRNA (adenosine-N6)-methyltransferases Entry into meiosis Ime4 METTL3
Trimethylguanosine synthases Hypermethylation of m(7)G to the
m(2,2,7)G 5′ cap of snRNAs, snoRNAs
and telomerase TLC1 RNA
Tgs1 TGS1
Probable rRNA (cytosine-5-)-methyltransferases 27S pre-rRNA processing and 60S ribosome
biogenesis
Nop2 NOP2
rRNA (guanine-N7)-methyltransferases rRNA processing Bud23 WBSCR22
rRNA (adenine-N6,N6-)-dimethyltransferases 18S pre-ribosomal rRNA processing Dim1 DIMT1, TFB1M
rRNA (2′-O-ribose)-methyltransferases 27S pre-rRNA and 25S rRNA processing,
60S ribosomal subunit maturation
Spb1 FTSJ1, FTSJ2, FTSJ3
Mitochondrial rRNA (2′-O-ribose)-
methyltransferases
Mitochondrial 21S rRNA processing Mrm1, Mrm2 MRM1
tRNA (guanine)-methyltransferases tRNA modiﬁcation Trm1, Trm5, Trm10, Trm8/Trm82,
Trm11/Trm112, Trm12
TRMT1, TRMTL1, TRMT5, RG9MTD2,
METTL1, TRMT11, TRMT12
tRNA (uracil-5-)-methyltransferases tRNA modiﬁcation Trm2, Trm9 TRMT2A, ALKBH8, KIAA145
tRNA (cytosine-5-)-methyltransferases tRNA modiﬁcation Ncl1 (Trm4) NSUN2, NSUN3, NSUN5
tRNA (adenine-N1-)-methyltransferases Maturation of initiator methionyl-tRNA Trm6/Trm61 TRMT6
tRNA (2′-O-ribose)-methyltransferases tRNA modiﬁcation Trm3, Trm7, Trm13, Trm44 TARBP1, FTSJ1, CCDC76
tRNA methyltransferases Methylation of N-4 position of yW-86 in
wybutosine biosynthesis
Tyw3 TYW3
Carboxyl methyltransferases Methylation of the α-carboxy group
of yW-72 in wybutosine biosynthesis
Ppm2 LCMT2
Proteins
Histone lysine N-methyltransferases Transcriptional elongation and silencing Set1, Set2, Dot1 SET superfamily consisting of SUV39,
SET1, SET2, RIZ, SMYD, EZ and SUV4-20
families, SET7/9, SET8, DOT1L
Ribosomal protein lysine
N-methyltransferases
Ribosome biogenesis Rkm1, Rkm2, Rkm3, Rkm4, Rkm5 SETD6
ω-NG-monomethylarginine and
asymmetric ω-NG,NG-dimethylarginine
methyltransferases
Methylation of hnRNPs affecting their activity
and nuclear export; methylation of U1 snRNP
protein Snp1p and ribosomal protein Rps2p
Hmt1 (Rmt1) PRMT1, PRMT3, PRMT4 (CARM1), PRMT6,
PRMT8
ω-NG-monomethylarginine and
symmetric ω-NG,NG-dimethylarginine
methyltransferases
Recruitment and inactivation of Swe1
(Wee1 ortholog) during mitotic entry
Hsl7 PRMT5 (JBP1), PRMT7
δ-NG-monomethylarginine
methyltransferase
Methylation of ribosomal protein Rpl12 Rmt2 –
Protein histidine methyltransferases 3-Methylhistidine modiﬁcation of ribosomal
protein Rpl3p
Hpm1 METTL18
N-terminal methyltransferases Methylation of ribosomal proteins Rpl12 and Rps25 Tae1 METTL11A
C-terminal leucine carboxyl
methyltransferases
Methylation of C-terminal leucine of PP2A catalytic
subunit, complex formation
Ppm1 LCMT1
Protein S-isoprenylcysteine
O-methyltransferases
C-terminal methylation of CAAX proteins Ste14 ICMT
Protein-L-isoaspartate (D-aspartate)
O-methyltransferase
Repair of damaged proteins − PCMT1
Cytochrome c lysine
N-methyltransferase
Trimethylation of cytochrome c, not
required for respiratory growth
Ctm1 −
eRF1 methyltransferases Peptidyl-glutamine methylation,
translation release
Mtq2 N6AMT1
Mrf1methyltransferases Peptidyl-glutamine methylation,
mitochondrial translation release
Mtq1 HEMK1
Lipids
Phospholipid N-methyltransferases Phosphatidylcholine de novo synthesis Cho2, Opi3 PEMT
Sterol 24-C-methyltransferase Ergosterol biosynthesis Erg6 –
Others
S-AdoMet-homocysteine
S-methyltransferase
Regulation of methionine/AdoMet ratio Sam4 –
Trans-aconitate methyltransferase Leucine biosynthesis Tmt1 –
Uroporphyrin-III C-methyltransferase Siroheme biosynthesis Met1 –
Glycine/sarcosine N-methyltransferase Regulation of hepatic AdoMet metabolism – GNMT
Guanidinoacetate N-methyltransferase Creatine synthesis – GAMT
Ubiquinone methyltransferases Ubiquinone biosynthesis, respiration Coq3, Coq5 COQ3, COQ5
Phenylethanolamine N-methyltransferase Adrenaline (epinephrine) biosynthesis – PNMT
Acetylserotonin O-methyltransferase Melatonin biosynthesis – ASMT
Histamine N-methyltransferase Histamine degradation – HNMT
Catechol O-methyltransferase Degradation of catecholamines – COMT
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Table 1 (continued)
AdoMet-dependent methyltransferases Biological function/process Yeast Mammalian orthologs
Indolethylamine N-methyltransferase Tryptamine methylation – INMT
Nicotinamide N-methyltransferases Nicotinamide metabolism Nnt1 NNMT
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yeast. While methylation of rRNA is crucial for ribosomal pro-
cessing and maturation [31], methylation of tRNA helps to con-
trol tRNA folding and to ensure decoding speciﬁcity and efﬁciency
[32]. Cap methylation at the 5′-terminal guanosine by mRNA (gua-
nine-7-)-methyltransferase is an essential process both in yeast and
mammals [33,34].
In addition to proteins and nucleic acids AdoMet-dependent
methyltransferases methylate lipids and a number of small molecules,
in particular, phosphatidylethanolamine, ubiquinone and nicotinamide
(Table 1). It is noteworthy that de novobiosynthesis of phosphatidylcho-
line from phosphatidylethanolamine catalyzed by AdoMet-dependent
phospholipid methyltransferases is the major AdoMet consumer in
mice and humans [35,36] as well as in yeast in the absence of choline/
ethanolamine supplementation.
3. The role of S-adenosyl-L-homocysteine hydrolase in
AdoMet-dependent methylation
AdoHcy that is released as a by-product of AdoMet-dependent
methyltransferase reactions, is a potent product inhibitor of most
AdoMet-dependent methyltransferases with Ki values in the
submicromolar to low micromolar range [37]. AdoHcy was shown to
inhibit a number of AdoMet-dependent methyltransferases in vitro,
such as mammalian DNA (cytosine-5-)-methyltransferase, mRNA cap
(guanine-N7-)-methyltransferase, tRNA (uracil-5-)-methyltransferase,
protein isoprenylcysteine carboxylmethyltransferase and phospholipid
methyltransferases [38–45], and in vivo, such as DNA (cytosine-5-)-
methyltransferase and phospholipid methyltransferases [7,46,47].
However, not all AdoMet-dependent methyltransferases exhibit
equal sensitivity against AdoHcy. While some AdoMet-dependent
methyltransferases have a Ki value for AdoHcy that is lower than
the Km value for AdoMet and are especially sensitive to AdoHcy [37],
others, in particular glycine N-methyltransferase, which regulates
AdoMet levels in mammals [1], are only weakly inhibited by AdoHcy
[48]. Being a potent product inhibitor for most AdoMet-dependent
methyltransferases, AdoHcy is a sensitive marker for the cellular
methylation status that is reﬂected by AdoMet/AdoHcy ratio, and can
be used to predict methylation deﬁciency e.g. DNA hypomethylation
[49].
The only eukaryotic enzyme capable of AdoHcy catabolism both in
yeast and mammals is S-adenosyl-L-homocysteine hydrolase (Sah1 in
yeast, AHCY in mammals), which catalyzes the reversible hydrolysis
of AdoHcy to homocysteine and adenosine. Similarly to AdoHcy ac-
cumulation, interference with S-adenosyl-L-homocysteine hydrolase
was shown to affect methylation of different targets of AdoMet-
dependent methyltransferases. In particular, inhibition of S-adenosyl-
L-homocysteine hydrolase and the resulting increase of AdoHcy levels
were shown to be associated with DNA hypomethylation in cultured
endothelial cells [46] and to interfere with RNAmethylation in cultured
lymphocytic leukemia cells [50]. Furthermore, inhibition of S-adenosyl-
L-homocysteine hydrolase was also shown to result in decreased
methylation of poly(A)(+) RNA in Xenopus laevis oocytes [51] as well
as in inhibition of phospholipid methylation in yeast [7]. In accordance
with the crucial role of AdoMet-dependent methylation in many
biological processes, accumulation of AdoHcy and/or S-adenosyl-L-
homocysteine hydrolase dysfunction is linked to numerous pathologies
including neurological and vascular disorders, myopathy, fatty liver,cancer, renal insufﬁciency and diabetic nephropathy [11,14,52–58].
The pathological consequences of AdoHcy accumulation as well as the
molecular mechanisms triggered by elevated AdoHcy levels are largely
not understood. Considering the role of AdoMet-dependent meth-
ylation in biological processes, inhibition of a number of AdoMet-
dependent methyltransferase reactions appears to play a central role
in AdoHcy-associated pathology. However, evidence of in vivo sensitiv-
ity of individual AdoMet-dependentmethyltransferase reactions aswell
as the responsiveness of methylation-dependent biological processes to
AdoHcy accumulation is limited. Since S-adenosyl-L-homocysteine hy-
drolase is a crucial physiological regulator of AdoHcy levels we will
discuss dysfunction of S-adenosyl-L-homocysteine hydrolase, its
evolutional conservation, structural organization and regulation in
the next sections.
4. S-adenosyl-L-homocysteine hydrolase dysfunction
Deletion of a locus overlapping the AHCY gene in mouse results
in embryonic death [59]. Homozygous insertion mutations in the
S-adenosyl-L-homocysteine hydrolase gene in Arabidopsis thaliana
result in zygotic lethality [60]. In contrast, yeast mutants lacking Sah1
are viable, due to the presence of an alternative pathway for homocys-
teine synthesis via the sulfur assimilation. Homocysteine that is synthe-
sized by this pathway is further used both for the synthesis of cysteine
and glutathione as well as for the synthesis of methionine and AdoMet
(Fig. 1) [7]. Introduction of an additional mutation in the sulfur as-
similation pathway indeed renders the resulting yeast sah1 mutants
inviable [7], consistent with an essential function of S-adenosyl-L-
homocysteine hydrolase.
S-adenosyl-L-homocysteine hydrolase deﬁciency in humans, a rare
genetic disorder, is characterized by up to 150-fold elevated plasma
AdoHcy levels with a signiﬁcant decrease in the AdoMet/AdoHcy ratio
and severe pathological consequences that can lead to death during
childhood [14,61–64]. In these patients, three tissues are predominantly
affected:muscles, brain and liver,manifested by severemyopathy, slow
myelination, developmental delay [61–63] aswell asmild hepatitis [61]
and lipid droplet accumulation in the liver [63]. Biochemical analyses
revealed that AHCY deﬁcient patients display 3–20% of mean control
S-adenosyl-L-homocysteine hydrolase activity in the liver, red blood
cells and ﬁbroblasts [61–63]. They exhibit a decrease of phosphatidyl-
choline, choline and albumin levels as well as an elevation of creatine
kinase, alanine transferase, aspartate transaminase [61–63] and lactate
dehydrogenase [63] levels in the plasma. At the cellular level these
patients show a proliferation of smooth and a decrease of rough en-
doplasmic reticulum [61], altered mitochondria [61,63] as well as
hypermethylation of leukocyte DNA [61–63].
5. S-adenosyl-L-homocysteine hydrolase: conservation, structure
and catalytic mechanism
S-adenosyl-L-homocysteine hydrolase is an exceptionally well-
conserved enzyme exhibiting over 70% identity at the protein level
between human and yeast orthologs, and is among the 90 most highly
conserved yeast proteins, including actin (90%), ubiquitin (90%), histones
(70–90%), ribosomal (70%) and heat shock proteins (70%) [65]. Fig. 2
displays a comparison of S-adenosyl-L-homocysteine hydrolase se-
quences fromArchaea, Bacteria and Eucarya. Emphasizing the similarity
of yeast and human orthologs, many bacterial and some eukaryotic
Fig. 2. S-adenosyl-L-homocysteine hydrolase: sequence and structural conservation.
The sequence conservation based on ConSurf calculations [160] using 166 unique
S-adenosyl-L-homocysteine hydrolase sequences is color coded (from blue – identity to
red – least conservation) and mapped onto the structure of the Pf-SAHH (PDB 1v8b
[77]). Shown is one monomer of the functional tetrameric S-adenosyl-L-homocysteine
hydrolase protein in cartoon drawing, the NAD+ cofactor (yellow) is shown in a stick
representation and the substrate (Ado) was omitted for clarity. Note that the 40 amino
acid insertion consisting of 3 helices and a loop (black circle), which is not present in
mammalian and yeast S-adenosyl-L-homocysteine hydrolases, shows the least degree of
conservation.
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sertion segment of 40 amino acids of as yet unknown function in the
catalytic domain of the enzyme [66].
S-adenosyl-L-homocysteine hydrolase belongs to the large family
of NAD(P)H/NAD(P)+-binding proteins that share a Rossmann-fold
[67]. The NAD(P)H/NAD(P)+ binding domain is found in numerous
dehydrogenases as well as in many other redox enzymes, but is rather
unusual for a hydrolase. The atomic structures of S-adenosyl-L-
homocysteine hydrolase from different sources have been resolved:
Homo sapiens (PDB 1a7a [68], PDB 1li4 [69] and PDB 3nj4 [70]), Rattus
norvegicus (PDB 1b3r [71], PDB 1ky4 and PDB 1ky5 [72], PDB 1k0u
[73], PDB 2h5l [74], PDB 1xwf [75] and PDB 1d4f [76]), Plasmodium
falciparum (PDB 1v8b [77]),Mycobacterium tuberculosis (PDB 3ce6, PDBFig. 3. Catalytic activity of S-adeno3dhy, PDB 2zj1, PDB 2zj0 and PDB 2ziz [78]), Burkholderia pseudomallei
(PDB 3d64), Trypanosoma brucei (PDB 3h9u) and Leishmania major
(PDB 3g1u) and the plant Lupinus luteus (PDB 3ond, PDB 3one and
PDB 3onf [79]).
All structurally characterized Sah1/AHCY proteins except plant
S-adenosyl-L-homocysteine hydrolase are tetramers with NADH/
NAD+ cofactor bound in the active site of each subunit [80,81].
Plant S-adenosyl-L-homocysteine hydrolase from L. luteus has been
shown to function as a homodimer [79]. The monomeric subunits
of the protein contain three domains: N-terminal substrate-binding do-
main, cofactor-binding domain and C-terminal tail. The C-terminal tails
of two subunits reciprocally protrude into opposite subunits and forma
part of their cofactor-binding sites [68]. The two dimers then form a
tetramer with the four cofactor-binding domains molding the central
core of the tetramer structure, and the substrate-binding domains
being exposed on the surface.
The thermodynamic equilibrium of the reaction catalyzed by
S-adenosyl-L-homocysteine hydrolase favors the synthesis of AdoHcy
from adenosine and homocysteine in vitro [82]. In vivo rapid enzy-
matic removal of homocysteine (Hcy) and adenosine (Ado) enables
the net hydrolysis of AdoHcy [82,83]. The reaction cycle requires
reciprocal oxidation–reduction of the substrate and NAD+ [84]. In
the ﬁrst step, the Ado 3′ hydroxyl group of adenosine (synthetic
reaction: Ado+Hcy→AdoHcy) or AdoHcy (hydrolytic reaction:
AdoHcy→Ado+Hcy) is oxidized to ketone by NAD+ resulting in
the formation of NADH (Fig. 3). In the next steps the proton is re-
moved from C4′ forming the carbanion intermediate, followed by its
cleavage and the release of water or Hcy, respectively. The catalytic
cycle is ﬁnished by the addition of Hcy or water to the C4′_C5′
double bond and reduction of the 3′ keto group under regeneration
of NAD+, forming AdoHcy or Hcy, respectively. Depending on the
presence of the substrate the protein undergoes large conformational
rearrangements [71,85–87]. Substrate (AdoHcy/Ado) binding induces
a structural transition from the open to the closed form of the enzyme,
and product (Ado/AdoHcy) release induces the transition back to the
open conformation [85].
6. S-adenosyl-L-homocysteine hydrolase: regulation and
localization
S-adenosyl-L-homocysteine hydrolase requires NAD+ to maintain
its quaternary structure and catalytic activity, making the enzyme
sensitive to the redox status of the cell that is reﬂected by thesyl-L-homocysteine hydrolase.
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L-homocysteine hydrolase is subject to reduction–oxidation cycles
during the reaction [84] (Fig. 3). Moreover, the form of NAD bound
to the enzyme determines binding of adenosine, the substrate for
the synthetic reaction and the inhibitor of the hydrolytic reaction. It
was shown that S-adenosyl-L-homocysteine hydrolase from bovine
kidney possesses two binding sites for adenosine: a low afﬁnity bind-
ing site located in the catalytic domain and a high afﬁnity binding site
located in the NAD+/NADH binding domain of the enzyme [88]. The
NAD+ form of S-adenosyl-L-homocysteine hydrolase binds adenosine
with low afﬁnity leading to the formation of 3′-keto-adenosine, re-
duction of the tightly bound NAD+ to NADH and adoption of the
closed conformation by the enzyme [88]. However, the enzymatically
inactive NADH form of the enzyme binds adenosine with high af-
ﬁnity, suggesting a role for adenosine in NADH-induced inhibition
of S-adenosyl-L-homocysteine hydrolase and potential function of
the enzyme as intracellular Ado-binding protein [88].
S-adenosyl-L-homocysteine hydrolase was also shown to bind
copper with high afﬁnity and is indeed the major copper binding pro-
tein in mouse liver [89,90]. It has a similar dissociation constant for
copper as albumin [89] and was suggested to serve as an intracellular
copper transporter with a putative function in delivering copper to
superoxide dismutase [91]. Copper inhibits S-adenosyl-L-homocysteine
hydrolase activity in a non-competitive manner due to the release of
NAD+ [92] that results from interruption of subunit interactions, which
leads to a large decrease in the afﬁnity for the NAD+ cofactor [92]. How-
ever, the signiﬁcance of regulation of S-adenosyl-L-homocysteine hy-
drolase by NAD+, adenosine and copper is not clear.
In yeast S-adenosyl-L-homocysteine hydrolase is primarily found
in the cytosol [93]. However, AdoMet-dependent methylation takes
place in different cellular compartments e.g. nucleus and ER, suggesting
that subcellular translocation of the enzymemay play a regulatory role.
Indeed, S-adenosyl-L-homocysteine hydrolasewas found in the nucleus
in association with mRNA (guanine-7-)-methyltransferase and RNA
polymerase II in transcriptionally active X. laevis oocytes [51,94].
S-adenosyl-L-homocysteine hydrolase was also shown to translocate
into the nucleus in adult mammalian cells under hypoxia conditions
known to induce transcriptional activity [95]. Localization analyses in
A. thaliana also demonstrated that the enzyme is capable of localizing
to the cytoplasm and the nucleus [96], and was proposed to be targeted
to the nucleus in a complex with adenosine kinase, another enzyme re-
quired for AdoHcy catabolism [96]. The S-adenosyl-L-homocysteine hy-
drolase/adenosine kinase complex is, presumably, targeted to the
nucleus by the nuclear localization signal of mRNA (guanine-7-)-
methyltransferase, with which it interacts [96].
7. AdoHcy in hyperhomocysteinemia
The pathological accumulation of homocysteine above the normal
plasma homocysteine level of 10 μmol/L, hyperhomocysteinemia, can
be caused by genetic or nutritional factors. Deﬁciency in cystathionine
β-synthase (Fig. 1) or genetic defects of folate and cobalamin metabo-
lisms lead to severe hyperhomocysteinemia characterized by the plasma
homocysteine levels of more than 100 μmol/L [97] and are rare in com-
parison to mild hyperhomocysteinemia. Mild hyperhomocysteinemia,
in turn, may be due to moderate deﬁciencies of key enzymes involved
in homocysteine metabolism, such as the thermolabile variant of
5,10-methylenetetrahydrofolate reductase gene that has been re-
ported in 5–15% of the general population [98]. Additionally, mild
hyperhomocysteinemia may be a result of dietary deﬁciencies of
vitamin cofactors required for homocysteine catabolism — folic acid,
vitamins B6 and B12, and is characterized by the plasma total homocys-
teine levels of 15–25 μmol/L [99]. Hyperhomocysteinemia is linked to a
number of disorders. It is recognized as a strong, independent and
causal risk factor for cardiovascular and vascular diseases [100–103].
In particular, it has been estimated that a 2.5 μM rise in homocysteinelevels corresponds to a 10% increase in cardiovascular disease risk
[104] and it was shown that about 40% of patients diagnosed with pre-
mature coronary artery disease, peripheral vascular disease or venous
thrombosis exhibit hyperhomocysteinemia [105]. In addition to vascu-
lar diseases hyperhomocysteinemia is also associatedwith a number of
other pathologies including neurological disorders, cancer, renal insuf-
ﬁciency, diabetes, birth defects and aging [55,56,104,106–109]. A num-
ber of potential mechanisms that are aimed at the explanation of the
pathological consequences resulting from homocysteine accumulation
were proposed [100,105,110]; however, there is still a controversy on
the underlying metabolic connections [111–113].
Since certain vitamin deﬁciencies are characterized by mild
hyperhomocysteinemia the possibility that vitamin supplementation
could reduce/prevent cardiovascular events was studied in several
large trials. However, it was observed that vitamins, while capable
of lowering elevated plasma homocysteine levels, do not reduce the
rates of vascular events [114]. This result may be due to the promo-
tion of cell proliferation by folic acid through its role in the synthesis
of thymidine, the increase of the methylation potential leading to
changes in gene expression, or an increase in the levels of asymmetric
dimethylarginine that inhibits the activity of nitric oxide synthase,
offsetting any positive effect of homocysteine lowering [114]. An ad-
ditional possibility is that a related metabolite rather than homocys-
teine could be a trigger of some pathological changes associated
with elevated homocysteine levels. Since the thermodynamic equilib-
rium of the S-adenosyl-L-homocysteine hydrolase reaction favors the
synthesis of AdoHcy [82], the accumulation of hydrolytic products
of the reaction, in particular, homocysteine leads to the reversal of
the physiological direction of the Sah1 catalyzed reaction, resulting
in AdoHcy synthesis and its accumulation in vivo, as shown both in
mammals as well as in yeast [7,83,115]. Indeed, patients with even
mild hyperhomocysteinemia (95% CI values for total homocysteine
11.0–14.7 μmol/L) that overlap those of controls (95% CI values 9.8–
12.2 μmol/L) exhibit signiﬁcant elevation of plasma AdoHcy (95% CI
values 32.3–47.7 nmol/L) compared to controls (95% CI values 24.9–
30.7 nmol/L) [116]. Therefore, even mild hyperhomocysteinemia is
characterized by an accumulation of AdoHcy, which may lead to a
decreased methylation potential and the inhibition of a number of
AdoMet-dependent methyltransferases and, thus, contribute to the
pathology associated with homocysteine accumulation.
Notably, the mechanisms that have been proposed to explain the
pathological changes associated with elevated homocysteine levels
do not address the accumulation of AdoHcy and the inhibition of
AdoMet-dependent methylation in homocysteine-associated pathol-
ogy, with the exception of an inhibition of DNA methylation [117–119].
However, AdoHcy rather than homocysteine was shown to be a more
sensitive indicator of cardiovascular disease [116,120] as well as of renal
insufﬁciency [56] suggesting that AdoHcy is indeed a crucial patholog-
ical factor in homocysteine-associated disorders. It was also reported
that the supplementation with B-vitamins including folate does not
efﬁciently lower plasma AdoHcy levels in contrast to homocysteine
levels in elderly people with hyperhomocysteinemia [121], possibly
explaining the failure of homocysteine lowering vitamins to reduce
vascular eventsmentioned earlier. Furthermore, supporting the patho-
genic role of AdoHcy, studies in yeast showed that indeed AdoHcy but
not homocysteine is more toxic to cells that are deﬁcient in homocys-
teine catabolism [122].
8. Induced AdoHcy accumulation as a strategy towards antiviral
therapy
During the last three decades S-adenosyl-L-homocysteine hydro-
lase was intensively studied as a target for antiviral drug design [123].
Inhibitors that block the enzyme are efﬁcient against many types of
viruses, including Ebola, that are dependent, in particular, on mRNA
methylation [123–125]. In addition to antiviral activity inhibitors
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fects of pharmacological importance, for instance, antimalarial and im-
munosuppressive activity [126,127]. Although AdoHcy accumulation
may be responsible for a number of the effects of inhibitors targeted
at S-adenosyl-L-homocysteine hydrolase, the ability of some of these
inhibitors to undergo metabolic phosphorylation to nucleotides may
account for a part of their biological activities, making it difﬁcult to val-
idate themode of their action [128]. Furthermore, the interferencewith
central metabolic pathways associated with high cytotoxicity is an ad-
ditional hindrance in the utilization of S-adenosyl-L-homocysteine hy-
drolase inhibitors in the potential future clinical applications [125].
Nevertheless, suppression of viral replication in plants by controlled
downregulation of S-adenosyl-L-homocysteine hydrolase conﬁrms
the antiviral activity as a result of AdoHcy accumulation [129].
9. Yeast as a model system to study methylation deﬁciency
Numerous disorders associated with AdoHcy accumulation sug-
gest that this metabolite is capable of triggering multiple pathological
mechanisms, presumably via inhibition of different AdoMet-dependent
methyltransferases. However, the role of AdoHcy in these diseases as
well as the AdoHcy-dependent molecular mechanisms contributing
to the consequences inherent to these pathologies is poorly understood.
Of course, understanding the responsiveness ofmethylation-dependent
processes requiring AdoMet-dependent methyltransferases that are
present only inmammals, e. g. protein L-isoaspartatemethyltransferase,
requires the use of a mammalian model system. However, due to the
complexity of themethylationmetabolism its dissection in amulticellular
organism as well as in higher cells is rather difﬁcult.
The yeast Saccharomyces cerevisiae is a unicellular eukaryote with
an about 4 times lower number of genes compared to humans, but
shares the complexity of the cellular architecture of higher cells.
Yeast is especially amenable to experimentation, in particular for ge-
netic manipulation and whole genome studies. As a result, this model
system is prized with the highest genome annotation level and was
successfully used to characterize a number of fundamental biological
processes, including secretion, organelle biogenesis and cell cycle
[130–133]. Yeast exhibits a highly conserved methylation metabolism
[17,65] and as such is an advantageous system to understand funda-
mental toxicity of AdoHcy at the cellular level. For instance, yeast
mutants capable of reproducible down-regulation of S-adenosyl-
L-homocysteine hydrolase and, thus, in vivo modulation of AdoHcy
levels can be used as a valuable tool to understand downstream
mechanisms triggered by AdoHcy accumulation. Usage of a yeast mu-
tant that is deﬁcient in homocysteine remethylation to methionine,
met6, provides another independent system to understand the role
of AdoHcy. In this mutant, grown under homocysteine supplementa-
tion, elevated homocysteine leads to AdoHcy synthesis via the rever-
sal of S-adenosyl-L-homocysteine hydrolase reaction resulting in an
accumulation of the latter. However, in this mutant elevated homo-
cysteine cannot be remethylated to methionine, impeding an addi-
tional increase in AdoMet levels and an elevation of the AdoMet/
AdoHcy ratio. Further advantage of this system is that it uncouples
the S-adenosyl-L-homocysteine hydrolase function in the regulation
of AdoMet-dependent methylation from its potential effect on gluta-
thione levels. Both systems were already shown to help in the identi-
ﬁcation and characterization of critical cellular processes that respond
to AdoHcy accumulation [7]. In the next section the deregulation of
lipid metabolism, the major consumer of AdoMet both in yeast and
in mammals, will be discussed, as a special aspect of AdoHcy toxicity.
10. Role of AdoHcy in lipid metabolism
Changes at the epigenetic level are the most extensively studied
consequences of methylation deﬁciency [117–119]. However, quanti-
tatively the most important AdoMet-dependent methyltransferasestake part in theprimarymetabolism. Phospholipidmethylation requires
three sequential AdoMet-dependent methylation steps to synthesize
one molecule of phosphatidylcholine (PC) from phosphatidyletha-
nolamine (PE) de novo. Whereas in yeast phospholipid methylation
is the predominant way to synthesize PC (in particular, in the absence
of choline/ethanolamine in the culture medium), phospholipid meth-
ylation in mammals that occurs primarily in the liver covers only 30%
of hepatic PC synthesis and accounts for estimated 10 μmol and
1.65 mmol PC secreted into bile per day in mice and humans, respec-
tively [36]. Phospholipid methylation is the major AdoMet consumer
in yeast in the absence of choline/ethanolamine supplementation.
Despite of the relatively low contribution of phospholipid de novo syn-
thesis to PC production in mammals this reaction is also the major con-
sumer of AdoMet in mice [35]. Reexamination of the methylation
metabolism in humans also revealed that phospholipid methylation,
but not creatine synthesis as was assumed previously, accounts for the
major part of AdoMet being utilized in the human body [36].
10.1. AdoHcy in yeast lipid metabolism
The involvement of S-adenosyl-L-homocysteine hydrolase in the
regulation of phospholipid biosynthesis in yeast was found by show-
ing that yeast SAH1 is regulated at the transcriptional level in coordina-
tion with phospholipid biosynthesis [134]. S-adenosyl-L-homocysteine
hydrolase controls phospholipid de novomethylation in yeast by regu-
lating the hydrolysis of AdoHcy, which is a competitive inhibitor of
Cho2 and Opi3 phospholipid methyltransferases that catalyze methyla-
tion of PE to PC [7,45] (Fig. 4). However, not only phospholipid methyl-
ation, but also amethylation-independent branch of lipidmetabolism is
affected by AdoHcy accumulation in yeast: yeast cells deﬁcient in
AdoHcy catabolism massively accumulate triacylglycerols (TAG) [7].
Supporting the causal role of impaired phospholipid methylation in
the deregulation of TAG metabolism in response to AdoHcy accumula-
tion, it was found that yeast mutants that are deﬁcient in the enzymatic
activities required for methylation of PE to PC, cho2 and opi3, also accu-
mulate TAG [7]. Additionally, homocysteine supplementation in yeast
that leads to a 10-fold accumulation of AdoHcy results in the inhibition
of phospholipid methylation and accumulation of TAG, conﬁrming a
crosstalk between homocysteine and lipid metabolism [7].
In addition to TAG metabolism, transcriptional regulation of phos-
pholipid biosynthesis is also affected in mutants impaired in AdoHcy
catabolism. Deﬁcient phospholipidmethylation in Sah1 depletedmutant
cells unable to hydrolyze AdoHcy, or in cho2 and opi3mutants, leads to
induced expression of phospholipid biosynthetic (UASINO-responsive)
genes, indicating accumulation of the phospholipid precursor, phos-
phatidic acid, in the endoplasmic reticulum (ER) [7]. ACC1 encoding
acetyl-CoA carboxylase, the ﬁrst and rate-limiting enzyme of fatty
acid biosynthesis, is also subject to UASINO-mediated regulation. There-
fore, the inhibition of phospholipidmethylation inmutants deﬁcient in
AdoHcy catabolism aswell as in cells supplementedwith Hcy appear to
result in an accumulation of fatty acids and their channeling into TAG,
which play a crucial role in buffering excess fatty acids [135].Moreover,
in addition to a deregulated phospholipid and triacylglycerol metabo-
lism, down-regulation of SAH1 expression in yeast also impairs sterol
synthesis leading to 4-fold elevated squalene levels. This suggests
an accumulation of early precursors of ergosterol biosynthesis under
these conditions, presumably as a result of inhibition of sterol
24-C-methyltransferase (Tehlivets, Kohlwein, unpublished).
10.2. AdoHcy and homocysteine in lipid metabolism in mammals
AdoHcy also inhibits mammalian phosphatidylethanolamine
N-methyltransferase (PEMT) [136,137]. Similarly as in yeast, deﬁciency
of phospholipid methylation in PEMT−/− knockout mice leads to a
rapid decrease of the hepatic PC/PE ratio and accumulation of TAG in
the liver, in the absence of choline supplementation [138]. However,
Fig. 4. Role of AdoHcy and S-adenosyl-L-homocysteine hydrolase in lipid metabolism in yeast. AdoMet, S-adenosyl-L-methionine; AdoHcy, S-adenosyl-L-homocysteine; Hcy, homocys-
teine; Met, methionine; Sah1, S-adenosyl-L-homocysteine hydrolase; CTT, cystathionine; Sam1, AdoMet synthetase 1; Sam2, AdoMet synthetase 2; Sam4, AdoMet-homocysteine
methyltransferase; Mht1, S-methylmethionine–homocysteine methyltransferase; Met6, methionine synthase; Met25, O-acetylhomoserine sulfhydrylase; Str1, cystathionine γ-lyase;
Str2, cystathionine γ-synthase; Str3, cystathionine β-lyase; Str4, cystathionine β-synthase; Gsh1, γ-glutamylcysteine synthetase; Gro, glycerol; DHAP, dihydroacetone phosphate; LPA,
lysophosphatidic acid; PA, phosphatidic acid; DAG, diacylglycerol; TAG, triacylglycerol; CDP-DAG, CDP-diacylglycerol; Cho, choline; Etn, ethanolamine; CL, cardiolipin; PG,
phosphatidylglycerol; PGP, phosphatidylglycerol phosphate; Glc, glucose; Ins, inositol; PI, phosphatidylinositol; PS, phosphatidylserine; PE, phosphatidylethanolamine; PC, phosphatidyl-
choline; Cho2, phosphatidylethanolaminemethyltransferase catalyzing ﬁrst methylation from PE to PC; Opi3, phospholipidmethyltransferase catalyzing two last methylation steps from
PE to PC.
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creased TAG secretion from hepatocytes [139].
Elevated levels of homocysteine are also linked to the deregula-
tion of lipid metabolism in mammals. Cystathionine β-synthase−/−
knockout mice exhibit severe hyperhomocysteinemia and accumulate
AdoHcy in all tissues tested [53,140]. These mutant animals show ele-
vated TAG and nonesteriﬁed fatty acid levels in the liver and serum,
and develop hepatic steatosis [12]. Another genetic disorder that results
inmoderately elevated homocysteine levels,methylenetetrahydrofolate
reductase deﬁciency, leads to fatty liver development as well as to
neuropathology and aortic lipid deposition in mouse model systems
[10,141]. Additionally, dietary-induced hyperhomocysteinemia in mice
also causes fatty liver [142] suggesting that AdoHcy accumulation and
impaired phospholipid methylation are common denominators in
homocysteine-associated pathologies.
10.3. Activation of UPR and deregulation of unsaturated fatty acid
metabolism in AdoHcy-related deﬁciencies
Supporting the role of elevated homocysteine levels in the deregula-
tion of lipid metabolism in mammals, homocysteine supplementationwas shown to lead to the activation of the sterol regulatory element-
binding proteins (SREBPs), which function to activate genes encoding
enzymes in cholesterol, fatty acid and triacylglycerol biosynthesis
and uptake pathways, both in cultured mammalian cell lines as well as
in the livers of CBS−/− mice that lack cystathionine β-synthase
[142,143]. The ﬁnding that overexpression of the ER chaperone GRP78/
BiP inhibits homocysteine-induced gene expression [142,144] suggests
that unfolded protein response (UPR) induction plays a direct role in
the activation of triacylglycerol and cholesterol biosynthesis in response
to homocysteine accumulation in mammals. One of the possible mecha-
nisms responsible for the induction of ER stress and UPR activation in re-
sponse to homocysteine accumulation is the accumulation of saturated
fatty acids in membrane phospholipids [145–147]. In accordance,
overexpression of stearoyl-CoA desaturase was shown to attenuate
palmitate-induced ER stress and protect from lipoapoptosis in mam-
malian cells [148–150].
Phospholipid methyltransferases preferentially catalyze synthesis
of PC containing di-C16:1 species in yeast both in vitro and in vivo
[151]. In line, the PEMT-derived PC pool is also enriched in unsaturated
fatty acids [152,153]. Supporting the role of PEMT in the metabolism
of unsaturated fatty acids, PEMT−/− knockout mice were reported to
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with the control littermates [154], and to exhibit dramatically reduced
concentrations of polyunsaturated fatty acids in the plasma and in he-
patic PC, independently of the choline status [155]. Moreover, both
AdoHcy and homocysteine accumulation are linked to decreased levels
of unsaturated fatty acids. It was shown in particular, that elevated plas-
ma AdoHcy levels are negatively correlated with both PC content and
the level of polyunsaturated fatty acids in PC in red blood cells in
Alzheimer patients [156]. Furthermore, elevated plasma homocysteine
levels were shown to be associated with a decrease in polyunsaturated
(docosahexaenoic) fatty acids in the plasma of healthy humans [157]
and in the plasma and erythrocytes of cystic ﬁbrosis patients [158].
It was proposed that deﬁciency of phospholipid methylation due to
AdoHcy accumulation leads to an increase in saturated PC molecular
species in ER membranes followed by ER stress, protein misfolding,
induction of UPR and activation of lipid metabolism [159].
11. Concluding remarks and future perspectives
With 70% identity between yeast and human orthologs S-adenosyl-L-
homocysteine hydrolase, which catalyzes the reversible hydrolysis of
AdoHcy to homocysteine and adenosine, is among themost conserved
S. cerevisiae proteins, pointing to its central role in the cellular metab-
olism. Moreover, accumulation of homocysteine, characteristic to the
common pathological condition, hyperhomocysteinemia, “mimics”
S-adenosyl-L-homocysteine hydrolase dysfunction, due to the reversal
of the S-adenosyl-L-homocysteine hydrolase reaction resulting in the
synthesis and accumulation of AdoHcy.
Homocysteine is linked to numerous diseases, however, the mech-
anisms responsible for the pathological consequences associated with
these disorders are still elusive. Most importantly, AdoHcy rather
than homocysteine is recognized since recently as a more sensitive
marker of several homocysteine-associated pathologies.
As a product inhibitor of a number of AdoMet-dependent methyl-
transferases AdoHcy can trigger multiple pathological mechanisms.
Due to the complexity of methylation metabolism comprehension of
these mechanisms requires a systematic approach. Yeast as a validat-
ed unicellular model system particularly amenable to genomic ap-
proaches offers new possibilities to understand cellular responses to
AdoHcy accumulation. Our recent work conﬁrms that this system
can be successfully used for identiﬁcation and characterization of
AdoHcy responsive cellular processes that are relevant for humans.
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